Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2025 06:30 ET | Source: Interpace Biosciences, Inc.

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the...
January 09, 2025 18:07 ET | Source: Interpace Biosciences, Inc.

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Local...
June 04, 2024 08:00 ET | Source: Interpace Biosciences, Inc.

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of...